---
schema_version: "secwatch.filing_event.v1"
accession: "0000944809-22-000041"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:45:14.559666+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OPKO Health Q2 net loss of $101.7M on $309.9M revenue; NGENLA launch, ModeX acquisition

## Summary
- Acquired ModeX for $300M in stock; Dr. Zerhouni appointed President/Vice Chairman, Dr. Nabel Chief Innovation Officer.
- Pfizer launched NGENLA in Europe/Japan; OPKO received $85M milestone payment.
- Closed GeneDx sale to Sema4 for ~$322M upfront (cash + shares) plus up to $150M milestones.
- BRL diagnostics revenue fell to $186.8M from $397.2M; COVID PCR tests dropped to 0.9M from 2.8M.
- Net loss includes $71.2M non-cash charge from Sema4 stock decline; operating loss of $10.7M.

## SEC filing metadata
- accession: 0000944809-22-000041
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000094480922000041/0000944809-22-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000094480922000041/opk-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000944809-22-000041
- JSON: https://secwatch.observer/filing/0000944809-22-000041.json
- Plain text: https://secwatch.observer/filing/0000944809-22-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.